Singulex abandons IPO amid economic gloom
This article was originally published in Clinica
Diagnostic firm Singulex has shelved its planned initial public offering (IPO), citing poor market conditions. The Alameda, California company initially filed for the IPO with the US Securities and Exchange Commission on 28 September but since then the path to becoming a publicly-listed company has been far from smooth: it later reduced the amount it was looking to raise from $86 million to $74 million (www.clinica.co.uk, 25 October 2012) then, in November, postponed the IPO. Singulex had planned to list under the ticker symbol SGLX.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.